Clin Infect Dis by Smith, Bryce D. et al.
Hepatitis C Virus Antibody Positivity and Predictors Among 
Previously Undiagnosed Adult Primary Care Outpatients: Cross-
Sectional Analysis of a Multisite Retrospective Cohort Study
Bryce D. Smith1, Anthony K. Yartel2, Katherine Krauskopf3, Omar I. Massoud4, Kimberly A. 
Brown5, Michael B. Fallon6, and David B. Rein7
1Division of Viral Hepatitis, Centers for Disease Control and Prevention
2Centers for Disease Control and Prevention Foundation, Atlanta, Georgia
3Icahn School of Medicine at Mount Sinai, New York, New York
4University of Alabama at Birmingham
5Henry Ford Hospital, Detroit, Michigan
6University of Texas at Houston
7NORC at the University of Chicago, Illinois
Abstract
Background—Hepatitis C virus (HCV) testing guidance issued by the Centers for Disease 
Control and Prevention in 1998 recommends HCV antibody (anti-HCV) testing for persons with 
specified risk factors. The purpose of this study was to determine the prevalence and predictors of 
anti-HCV positivity among primary care outpatients and estimate the proportion of unidentified 
anti-HCV-positive (anti-HCV+) persons using risk-based testing.
Methods—We analyzed electronic medical record data from a 4-site retrospective study. Patients 
were aged ≥18 years, utilized ≥1 outpatient primary care service(s) between 2005 and 2010, and 
had no documented evidence of prior HCV diagnosis. Among persons tested for anti-HCV, we fit 
a multilevel logistic regression model to identify patient-level independent predictors of anti-HCV 
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positivity. We estimated the proportion of unidentified anti-HCV+ persons by using multiple 
imputation to assign anti-HCV results to untested patients.
Results—We observed 209 076 patients for a median of 5 months (interquartile range, 1–23 
months). Among 17 464 (8.4%) patients who were tested for anti-HCV, 6.4% (n = 1115) were 
positive. We identified history of injection drug use (adjusted odds ratio [95% confidence interval], 
6.3 [5.2–7.6]), 1945–1965 birth cohort (4.4 [3.8–5.1]), and elevated alanine aminotransferase 
levels (4.8 [4.2–5.6]) as independently associated with anti-HCV positivity. We estimated that 
81.5% (n = 4890/6005) of anti-HCV+ patients were unidentified using risk-based testing.
Conclusions—In these outpatient primary care settings, risk-based testing may have missed 4 of 
5 newly enrolled patients who are anti-HCV+. Without knowing their status, unidentified anti-
HCV+ persons cannot receive further clinical evaluation or antiviral treatment, and are unlikely to 
benefit from secondary prevention recommendations to limit disease progression and mortality.
Keywords
hepatitis C virus (HCV); anti-HCV prevalence; predictors of HCV positivity; outpatient primary 
care; HCV testing
Hepatitis C virus (HCV) infection is an urgent health problem, with an estimated 4 million 
persons ever infected and approximately 3 million chronically infected in the United States 
[1,2].It is estimated that 45%–60% of adults with HCV infection will develop cirrhosis over 
the next 2–5 decades [3, 4]. In 2010, HCV infection was the underlying or contributing 
cause of >16 500 deaths in the United States [5].Advances in antiviral therapy have resulted 
in the potential for dramatic reductions in morbidity and mortality among persons treated for 
HCV infection [6–9], but care and treatment can only be provided to those infected persons 
who are tested and identified.
In 1998, Centers for Disease Control and Prevention (CDC) recommended routine HCV 
antibody (anti-HCV) testing for persons with specified risk factors and medical indications 
including history of injection drug use (IDU), persistently elevated alanine aminotransferase 
(ALT) levels, blood transfusion or organ transplant before 1992, clotting factor concentrates 
before 1987, and long-term hemodialysis [10]; in 1999, the US Public Health Service and 
the Infectious Diseases Society of America jointly recommended HCV testing for all human 
immunodeficiency virus (HIV)-infected adults [11]. Several noninterventional studies have 
since examined the effectiveness of risk-based testing among persons receiving care in 
clinical settings or persons with access to healthcare; the studies have compared the overall 
observed anti-HCV prevalence—defined as the number of identified persons divided by the 
total population of patients (tested and not)— to the expected prevalence as determined by 
population surveys or modeling [12–15]. Among patients enrolled in an urban managed care 
organization, Roblin et al determined that the overall observed anti-HCV prevalence was 
0.2% [12]; using a population of patients enrolled in 4 private healthcare organizations, 
Spradling et al found an overall observed prevalence of approximately 0.9% [13]; other 
researchers have found higher observed prevalence rates ranging from 2.5% to 4.6% among 
predominantly African American and Hispanic populations receiving routine care in urban 
primary care settings [14, 15]. Unanimously, the overall observed anti-HCV prevalence in 
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these settings has been described as lower than expected and the proportion of unidentified 
anti-HCV positive persons has been estimated as ranging from 40% to 85% [12–16].
In 2012, CDC augmented the risk factor– and medical indication–based HCV screening 
strategies by issuing a recommendation to test all persons born during 1945–1965 without 
prior risk ascertainment [17]. Persons in this cohort account for an estimated three-quarters 
of all HCV infections and HCV-associated deaths in the United States [18, 19]. In 2013, the 
US Preventive Services Task Force also revised its recommendations to include this birth 
cohort based on their review of the available evidence [20].
This study sought to determine anti-HCV prevalence and factors associated with anti-HCV 
positivity in a large geographically and demographically diverse cohort of adult primary care 
outpatients with no previous diagnosis of HCV. We also aimed to estimate the proportion of 
unidentified anti-HCV-positive (anti-HCV+) persons within this cohort.
METHODS
Study Design
We conducted a cross-sectional analysis using electronic medical record (EMR) data of 
patients from the Birth Cohort Evaluation to Advance Screening and Testing for HCV 
(BEST-C), a multisite retrospective cohort study.
Study Setting and Participants
Participants in BEST-C included all newly enrolled patients aged ≥18 years with no previous 
diagnosis of anti-HCV who utilized at least 1 primary care outpatient service in 4 large 
healthcare centers (sites): Mount Sinai Medical Center (MSMC); University of Alabama at 
Birmingham (UAB); University of Texas, Houston (UTH); and Henry Ford Hospital System 
(HFH). The study spans 6 years from January 2005 to December 2010 (MSMC, UAB, 
UTH) or from March 2005 to March 2011 (HFH). Participants with missing values for date 
of first encounter were excluded.
Only new patients with a first-time encounter through primary care were included in this 
study based on the understanding that health screening is most likely to occur for new 
patients [16]; patients with documentation of HCV diagnosis at the time of first encounter 
were excluded. Data on patient demographics, clinical characteristics, and anti-HCV testing 
were collected at each patient’s first visit and at successive encounters during the study 
period to create an encounter-level dataset. Encounter-level data were summarized to create 
a patient-level dataset. The current analysis is based on 209 076 patients. We calculated the 
period of observation (in months) as the date of last visit minus date of first visit; patients 
with a single visit were coded as observed for 1 month.
Outcome Variables
The main outcome measure for this analysis was anti-HCV positivity. We defined anti-HCV 
positivity as a positive test result for antibodies to HCV by enzyme-linked immunoassay at 
any visit during the study period.
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Independent Variables
Independent variables previously associated with anti-HCV positivity were selected for this 
analysis [12, 14, 21]. Demographic variables examined included birth year, race/ethnicity, 
sex, marital status, and annual census tract–level income. Census tract income was used as a 
proxy for household income, which was unavailable. Birth year was dichotomized as born 
during 1945–1965 or born outside the 1945–1965 birth cohort. Race/ethnicity was 
categorized as white, black, Hispanic, Asian, or other. Sex was classified as male or female. 
Marital status was categorized as married, divorced/separated/widowed, or never married. 
Income was categorized as <$30 000, $30 000–$49 999, $50 000–$69 000, $70 000–$99 
000, and ≥$100 000. We also examined the following clinical variables: history of IDU, 
elevated ALT, hemophilia, HIV infection, and total number of patient encounters with health 
system during the study period. History of IDU was defined as having an International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis 
code for IDU (292, 304, 305, 969.7, 970.8, 965.01) documented in the EMR at any time 
during the study period. This search strategy was augmented by text query of the EMR for 
evidence of IDU. Patients were coded as having a history of elevated ALT if a laboratory 
record for ALT test with abnormal result was associated with the EMR at any visit during 
the study period. Cutoff levels used to establish elevated ALT were sex- and site-specific. 
Hemophilia (ICD-9-CM 286.52, 286.5) and HIV infection (ICD-9-CM V08, 042) were 
similarly identified. Identification of HIV infection was enhanced by search of text notes in 
the EMR. Data regarding other known covariates of anti-HCV positivity such as 
hemodialysis and blood transfusion before 1992 were not included in this analysis due to 
lack of consistency in data collection across sites. History of IDU, hemophilia, HIV 
infection, and elevated ALT were coded as yes or no/unknown.
Statistical Analysis
Multiple Imputation of Missing Data—Overall, about 51.0% of all patients had missing 
data for at least 1 demographic variable. To maintain statistical power and to avoid potential 
bias in statistical estimates [22], we used IVE-ware version 0.1 to replace missing values by 
multiple imputation using the method of sequential regression multivariate imputation [23]. 
Imputed datasets were individually analyzed with standard software and summarized per the 
Rubin method with appropriate adjustment for degrees of freedom [24] (Supplementary 
Appendix).
Statistical Estimates—Statistical significance for all tests was set at a 2-tailed P value 
of .05. We calculated proportions to describe the characteristics of the overall study 
population as well as the subpopulation of patients who were tested for anti-HCV at any 
time during the study period. Overall observed prevalence [13, 14] was estimated by 
dividing the total number of anti-HCV+ persons by the total number of all participants 
(tested or not). This approach assumes that because testing is driven by risk factors and 
medical conditions, patients who are not tested are more likely to be negative for anti-HCV. 
Expected prevalence was estimated by extending multiple imputation to anti-HCV status for 
patients who were not tested (Supplementary Appendix). Specifically, imputed anti-HCV 
values were assigned to each patient who was not tested, fully conditional on all data 
observed for that patient. The proportion of unidentified anti-HCV+ persons was 
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subsequently estimated as the difference between expected prevalence and observed 
prevalence divided by expected prevalence in the study population. We performed sensitivity 
analyses to assess effect of duration of follow-up on this estimate.
Among patients who were tested for anti-HCV during the 6-year study period, we calculated 
anti-HCV positivity by dividing the total number of anti-HCV+ patients by the total number 
of tested patients. To account for clustering of patients within study sites, we used univariate 
generalized linear mixed models to test for differences in anti-HCV positivity by patient 
characteristics [25]. We also fit a prespecified multilevel multiple logistic regression model 
adjusting for the random effect of site to identify independent correlates of anti-HCV 
positivity among patients tested. The dependent variable was anti-HCV positivity. Patient-
level independent variables included the following: birth year, sex, race/ethnicity, marital 
status, elevated ALT, IDU, hemophilia, HIV status, and total number of visits. Study site was 
modeled as a second-level random intercept. Census tract income was not included in this 
model as the variable was not measured at either the site level or the patient level. Sensitivity 
analysis was performed by comparing estimates from the multiply imputed data to results of 
complete case analysis. Unless otherwise indicated, we used SU-DAAN (version 10.0.1) and 
SAS (version 9.3) software to analyze data.
RESULTS
Characteristics of Study Population
A total of 209 076 patients were included in the analysis. The median length of observation 
was 5 months with an interquartile range of 1 to 23. A summary of the demographic and 
clinical characteristics of patients is presented in Table 1.
Observed and Expected Prevalence Estimates
The overall observed prevalence (ie, the rate of anti-HCV identification) among all patients 
was 0.53% (n = 1115/209 076). Using multiply imputed anti-HCV values for patients who 
were not tested, we estimated the corresponding expected prevalence to be 2.87% (n = 
6005/209 076), with a range of 0.84% to 4.34% across the 4 sites. We further estimated that 
81.5% (n = 4890/6005) of anti-HCV+ persons were not identified using risk-based testing 
strategy (Table 2). Upon restricting the analytic data to new patients who had been enrolled 
in the health system for at least 12 months (median follow-up = 30 months), the proportion 
of unidentified anti-HCV patients was estimated at 80%; a restricted analysis of new patients 
who were enrolled for at least 24 months (median follow-up = 40 months) yielded a similar 
result (79%). Among patients born between 1945 and 1965, the estimated proportion of 
unidentified anti-HCV+ persons was 76% (ie, observed prevalence = 1.2%; expected 
prevalence = 4.9%).
Positivity Among Patients Tested
Among patients who were tested for anti-HCV, 6.4% (n = 1115/17 464) were positive (Table 
3). About 75% of all anti-HCV+ persons were born during 1945–1965. Anti-HCV positivity 
was significantly higher in patients born from 1945 to 1965 (13.8%) compared with the 
referent group of those born before 1945 or after 1965 (2.5%); blacks (12.1%) or Hispanics 
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(8.5%) relative to whites (5.0%); widowed/divorced/separated (10.4%) or never married 
(6.7%) compared with married (5.0%); and males (8.8%) vs females (4.4%) (Table 3). Anti-
HCV positivity was also greater in patients with a history of elevated ALT (14.9%), IDU 
(35.8%), hemophilia (10.7%), or HIV (17.3%).
Predictors of Anti-HCV Positivity Among Patients Tested
Following multivariate adjustment in a multilevel logistic regression model, we identified 
IDU (adjusted odds ratio [AOR], 6.3 [95% confidence interval {CI}, 5.2–7.6]), 1945–1965 
birth cohort (AOR, 4.4 [95% CI, 3.8–5.1]), elevated ALT (AOR, 4.8 [95% CI, 4.2–5.6]), 
black race (AOR, 1.9 [95% CI, 1.6–2.2]), Hispanic ethnicity (AOR, 1.5 [95% CI, 1.2–2.0]), 
widowed/divorced/separated (AOR, 1.5 [95% CI, 1.2–2.0]), never married (AOR, 1.4 [95% 
CI, 1.2–1.6]), and male sex (AOR, 1.3 [95% CI, 1.2–1.6]) as significant correlates of anti-
HCV positivity (Table 4). Hemophilia and HIV-positive status were not significantly 
associated with anti-HCV positivity. Sensitivity analysis using complete cases indicated that 
point estimates were comparable to results from the imputed data, imputation restored 
statistical efficiency and produced estimates with better precision (Table 5).
DISCUSSION
This is a multisite study in the United States examining anti-HCV positivity in a large cohort 
of newly enrolled, previously undiagnosed adult primary care outpatients from different 
regions of the country. We found that over a 6-year period, 6.4% of tested patients were anti-
HCV+. However, as the majority of patients were not tested, the observed prevalence was 
just above 0.5%. We estimated that the expected anti-HCV prevalence in this population 
could be as high as 2.9%, indicating that during the study period, >81% of anti-HCV+ 
persons may have been undetected.
The findings from this study are supported by previous research. Anti-HCV positivity 
among patients tested and the observed prevalence are comparable to results from Spradling 
et al, who used a similarly diverse population of patients with access to care: estimates for 
anti-HCV prevalence among patients tested and observed are 5.5% and 0.7%, respectively, 
when the data are restricted to patients with no history of HCV diagnosis [13]. Roblin et al 
also reported an anti-HCV positivity of 5.1% among patients tested and an overall observed 
prevalence of 0.2%, although the proportion of patients tested was considerably lower [12]. 
Southern et al [14] found a much higher prevalence of anti-HCV among patients tested 
(11.5%) and overall observed prevalence (4.6%), likely reflecting a higher local prevalence 
of HCV and HCV risk factors [26, 27] and a higher-than-average proportion of patients 
tested for anti-HCV of nearly 40% [14]. Our expected prevalence estimate can be reasonably 
compared to an estimate of 2.0% anti-HCV prevalence among US adults aged 20–70 years 
[18], accounting for the fact that African Americans, a high-prevalence group, are 
substantially overrepresented in the outpatient primary care cohort used for the current 
study. Moreover, our finding that testing based on risks or medical indications in the clinical 
setting underestimates anti-HCV prevalence by 81% is within the range of earlier findings 
[12–14]. Notably, our data further suggest that anti-HCV prevalence may vary regionally in 
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the United States (Table 2). This observation is supported by prevalence estimates from prior 
studies [14, 26, 28, 29].
Our analysis also indicated that patients’ birth year, history of IDU, and elevated ALT were 
significant correlates of anti-HCV positivity, as were black race, Hispanic ethnicity, single 
marital status, and male sex. History of IDU and elevated ALT as predictors of anti-HCV 
positivity are consistent with the data supporting risk-based testing recommendations [12, 
14, 15, 30]. Race, ethnicity, sex, and marital status have also previously been associated with 
anti-HCV positivity or current HCV infection [1, 13, 14]. Nevertheless, the finding that 74% 
of the identified anti-HCV+ patients were born from 1945 to 1965 provides additional data 
in support of recommendations by the CDC and the US Preventive Task Force [17, 20] for 
HCV testing in this birth cohort and confirms previous findings of the burden of prevalence 
in this cohort [13, 14, 19, 21].
This study has several strengths. The analysis of a large, demographically diverse, multisite, 
multiyear cohort of outpatient primary care patients representing different geographic 
regions of the country increases the potential generalizability of the findings. Also, the use 
of multilevel modeling to adjust for correlation between patients within sites (healthcare 
centers) ensures that standard error estimates are conservative. Moreover, the use of multiple 
imputation to replace missing data restored statistical power and improved precision of 
estimates.
However, there are also some important limitations. First, blood transfusion before 1992, an 
important determinant of anti-HCV positivity among older adults, was not included in this 
analysis due to a lack of consistent data collection across sites. Second, it is likely that risk 
factors such as IDU were underreported [31–35]; nondisclosure of relevant patient risk 
factors could lead to confounding of estimates [36]. Nonetheless, we determined that the 
proportions of patients identified as having history of IDU, hemophilia, HIV positivity, or 
elevated ALT were comparable to estimates reported in previous studies [12, 14, 16]. Third, 
cross-sectional analysis of this dataset limits our ability to assess temporal associations 
between independent risk factors and anti-HCV positivity; however, cross-sectional analysis 
was appropriate for other important objectives in this study such as estimates of anti-HCV 
prevalence and proportion of unidentified anti-HCV+ persons. Fourth, it is likely that 
retrospective review of EMR did not adequately identify patients diagnosed with HCV 
outside participating health systems prior to their first encounter; patients with a previous 
HCV diagnosis who were misclassified at the first encounter would have been included in 
the study and may not have received additional HCV testing during the study. In addition, 
we were unable to identify patients diagnosed outside participating health systems during 
the study, and our estimate of unidentified anti-HCV+ persons may be inflated as a result. 
Finally, in using multiple imputation to assign plausible values to missing data (sex, race/
ethnicity, marital status, expected anti-HCV prevalence), we assumed that missing values 
were missing at random (eg, missing data values for sex or anti-HCV status are related 
conditionally to observed patient characteristics) [22, 23]. Despite our efforts to make this 
assumption more plausible [25, 37] by including a large number of relevant predictors in the 
imputation models, the assumption may not be fully met because there is a good likelihood 
that not all patient variables were observed. Still, others have noted that missing data 
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originating from medical research are often related to observed patient data and that the 
missing-at-random assumption may be appropriate [22,38].
Despite these limitations, our findings demonstrate that testing based on risk and medical 
indications alone failed to identify four-fifths of previously undiagnosed adults with past 
exposure to HCV. This may be due in part to the difficulty in capturing complete patient risk 
history (eg, IDU) in EMRs to support the implementation of comprehensive risk–based 
HCV testing algorithms. HCV-infected persons who are not aware of their status cannot 
receive further clinical evaluation or antiviral treatment, and are unlikely to benefit from 
preventive services or secondary prevention recommendations (eg, reduction in alcohol use 
and other lifestyle changes) aimed at limiting disease progression and reducing liver-related 
morbidity and mortality [39, 40]. In the routine clinical environment, recent CDC and US 
Preventive Task Force recommendations to test patients born during 1945–1965 for HCV 
without the need for prior ascertainment of risk factors should be implemented [17, 20]. 
With the alignment of the risk-based and birth cohort testing recommendations, it is 
expected that identification of infected persons who were previously undiagnosed will 
increase, leading to higher rates of linkage to care and treatment as appropriate, or to 
programs that support linkage to care and treatment adherence, which would further result in 
reduced morbidity and mortality associated with HCV.
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Table 1
Characteristics of Study Population
Characteristic All Patients, No. (%) Patients Tested, No. (%)
Overall 209 076 (100) 17 464 (100)
Age, y, median (IQR)          37 (28–50)        37 (28–49)
1945–1965 birth cohort   70 718 (33.8) 5989 (34.3)
Female sexa 137 695 (65.6) 9706 (45.6)
Race/ethnicitya
 White   95 992 (45.9) 6554 (37.5)
 Black   58 437 (27.9) 6757 (38.7)
 Hispanic   14 526 (6.9) 1065 (6.1)
 Asian      9492 (4.5)   909 (5.2)
 Other   30 630 (14.7) 2179 (12.5)
Marital statusa
 Married   94 673 (45.3) 6434 (36.8)
 Widowed/divorced   15 866 (7.6) 1582 (9.1)
 Never married   98 537 (47.1) 9448 (54.1)
Income categorya
 <$30 000   34 561 (16.5) 3671 (21.0)
 $30 000–$49 999   58 227 (27.8) 5209 (29.8)
 $50 000–$69 000   51 440 (18.7) 4215 (24.1)
 $70 000–$99 999   39 145 (18.7) 2800 (16.03)
 ≥$100 000   25 704 (12.3) 1569 (9.0)
 Injection drug use      2992 (1.4) 1007 (5.8)
 Hemophilia      1241 (0.6)   299 (1.7)
 Elevated ALT   12 574 (6.0) 4618 (26.4)
 HIV infected      1240 (0.6)   767 (4.4)
Abbreviations: ALT, alanine aminotransferase; HIV, human immunodeficiency virus; IQR, interquartile range.
a
Missing values for sex, race/ethnicity, marital status, and income were multiply imputed.
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Table 3
Probability of Testing Hepatitis C Virus Antibody Positive, by Demographic and Clinical Characteristics
Characteristic Patients Tested, No. Patients Positive, No. (%) P Value*
Overall 17 464 1115 (6.4)   …
1945–1965 birth cohort 286
 No 11 475   286 (2.5)   …
 Yes 5989   829 (13.8) <.0001
Sexa
 Female 9706   429 (4.4)   …
 Male 7758   686 (8.8) <.0001
Race/ethnicitya
 White 6554   330 (5.0)   …
 Black 6757   574 (8.5) <.0001
 Hispanic 1065   129 (12.1) .0001
 Asian 909     16 (1.7) <.0001
 Other 2179     67 (3.1) .0119
Marital statusa
 Married 6434   319 (5.0)   …
 Widowed/divorced 1582   164 (10.4) <.0001
 Never married 9448   632 (6.7) .0178
Income categorya
 <$30 000 3671   366 (10.0) <.0001
 $30 000–$49 999 5209   361 (6.9) <.0001
 $50 000–$69 000 4215   225 (5.3) .0014
 $70 000–$99 999 2800   106 (3.8) .5743
 ≥$100 000 1569     57 (3.6)   …
Elevated ALT
 No/unknown 12 846   425 (3.3)   …
 Yes 4618   691 (14.9) .0001
Injection drug use
 No/unknown 16 457   754 (4.6)   …
 Yes 1007   365 (35.8) <.0001
Hemophilia
 No/unknown 17 165 1083 (6.3)   …
 Yes 299     32 (10.7) .0318
HIV infected
 No/unknown 16 697   982 (5.9)   …
 Yes 767   133 (17.3) .0045
Abbreviations: ALT, alanine aminotransferase; HIV, human immunodeficiency virus.
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a
Missing values for sex, race/ethnicity, marital status, and income were multiply imputed.
*P values obtained from univariate generalized linear mixed model incorporating random effect of site.
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Table 4
Model-Adjusted Odds Ratios for Hepatitis C Virus Antibody Positivity
Characteristic (n = 17 464) Adjusteda OR (95% CI) P Value
1945–1965 birth cohort
 No 1.0 …
 Yes 4.4 (3.8–5.1) <.0001
Sexb
 Female 1.0 …
 Male 1.4 (1.2–1.6) <.0001
Race/ethnicityb
 White 1.0 …
 Black 1.9 (1.6–2.2) <.0001
 Hispanic 1.5 (1.2–2.0) .0022
 Asian 0.6 (.4–1.1) .0874
 Other 1.1 (.8–1.5) .4142
Marital statusb
 Married 1.0 …
 Widowed/divorced 1.5 (1.2–2.0) .0019
 Never married 1.4 (1.2–1.6) .0003
Elevated ALT
 No/unknown 1.0 …
 Yes 4.8 (4.2–5.6) <.0001
Injection drug use
 No/unknown 1.0 …
 Yes 6.3 (5.2–7.6) <.0001
Hemophilia
 No/unknown 1.0 …
 Yes 1.1 (.7–1.7) .6207
HIV infected
 No/unknown 1.0 …
 Yes 1.0 (.8–1.3) .7571
Abbreviations: ALT, alanine aminotransferase; CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio.
a
Multilevel model adjusted for random effect of site and the following individual-level fixed effects: birth year, sex, race, marital status, injection 
drug use, elevated ALT, hemophilia, HIV status, and total number of encounters with healthcare system.
b
Missing values for sex, race/ethnicity, and marital status were multiply imputed.
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Table 5
Comparison Between Estimates From Multiply Imputed and Complete Case Analytic Models for Hepatitis C 
Virus Antibody Positivity
Characteristic
Adjusteda OR (95% CI)
Multiply Imputedb
(n = 17 464)
Complete Case
(n = 13 689)
1945–1965 birth cohort
 No 1.0 1.0
 Yes 4.4 (3.8–5.1)* 4.2 (3.2–5.5)*
Sex
 Female 1.0 1.0
 Male 1.4 (1.2–1.6)* 1.3 (1.0–1.6)
Race/ethnicity
 White 1.0 1.0
 Black 1.9 (1.6–2.2)* 1.8 (1.5–2.2)*
 Hispanic 1.5 (1.2–2.0)** 1.5 (1.1 –2.2)***
 Asian 0.6 (.4–1.1) 0.6 (.3–1.2)
 Other 1.1 (.8–1.5) 1.2 (.8–1.7)
Marital status
 Married 1.0 1.0
 Divorced/widowed 1.5 (1.2–2.0)** 1.5 (1.1 –2.0)***
 Never married 1.4 (1.2–1.6)* 1.4(1.1–1.7)***
Elevated ALT
 No/unknown 1.0 1.0
 Yes 4.8 (4.2–5.6)* 4.8 (3.7–6.2)*
Injection drug use
 No/unknown 1.0 1.0
 Yes 6.3 (5.2–7.6)* 6.4 (4.6–8.9)*
Hemophilia
 No/unknown 1.0 1.0
 Yes 1.1 (.7–1.7) 1.0 (.5–2.2)
HIV infected
 No/unknown 1.0 1.0
 Yes 1.0 (.8–1.3) 1.0 (.6–1.6)
Abbreviations: ALT, alanine aminotransferase; CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio.
aAdjusted for random effect of site and the following fixed effects: birth year, sex, race, marital status, injection drug use, elevated ALT, 
hemophilia, HIV status, and total number of encounters with healthcare system.
b
Missing values for sex, race/ethnicity, and marital status were multiply imputed.
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*P < .001.
**P values were between <.001 and <.01.
***P values were between <.01 and <.05.
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